keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer clinical trials

keyword
https://www.readbyqxmd.com/read/27919668/magnetic-resonance-imaging-provides-added-value-to-the-prostate-cancer-prevention-trial-risk-calculator-for-patients-with-estimated-risk-of-high-grade-prostate-cancer-less-than-or-equal-to-10
#1
Eric H Kim, John K Weaver, Anup S Shetty, Joel M Vetter, Gerald L Andriole, Seth A Strope
OBJECTIVES: To determine the added value of prostate MRI to the Prostate Cancer Prevention Trial risk calculator. METHODS: Between January 2012 and December 2015, 339 patients underwent prostate MRI prior to biopsy at our institution. MRI was considered positive if there was at least one Prostate Imaging Reporting and Data System 4 or 5 MRI suspicious region. Logistic regression was used to develop two models: biopsy outcome as a function of the 1) Prostate Cancer Prevention Trial risk calculator alone, and 2) combined with MRI findings...
December 2, 2016: Urology
https://www.readbyqxmd.com/read/27914560/diagnosis-and-treatment-of-testosterone-deficiency-recommendations-from-the-fourth-international-consultation-for-sexual-medicine-icsm%C3%A2-2015
#2
Mohit Khera, Ganesh Adaikan, Jacques Buvat, Serge Carrier, Amr El-Meliegy, Kostas Hatzimouratidis, Andrew McCullough, Abraham Morgentaler, Luiz Otavio Torres, Andrea Salonia
INTRODUCTION: Testosterone deficiency (TD), also known as hypogonadism, is a condition affecting a substantial proportion of men as they age. The diagnosis and management of TD can be challenging and clinicians should be aware of the current literature on this condition. AIM: To review the available literature concerning the diagnosis and management of TD and to provide clinically relevant recommendations from the Fourth International Consultation for Sexual Medicine (ICSM) meeting...
December 2016: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/27911459/evaluation-of-bone-metastases-by-18f-choline-pet-ct-in-a-patient-with-castration-resistant-prostate-cancer-treated-with-radium-223
#3
Piera Scalzi, Cinzia Baiocco, Sabrina Genovese, Antonella Trevisan, Zuzana Sirotova, Carlo Poti
BACKGROUND: To date, bone metastases remain the main cause of morbidity and mortality in patients with metastatic castration-resistant prostate cancer (mCRPC). Therefore, the combination of accurate early detection of bony disease and effective treatment of these lesions is crucial in the management of mCRPC patients, but clinical trials specifically designed to test novel approaches are currently lacking. CASE DESCRIPTION: This report describes the case of a 74-year-old male with bone mCRPC and symptomatic and biochemical progression, who underwent radium-223 therapy, following previous treatment failure...
December 2, 2016: Urologia
https://www.readbyqxmd.com/read/27910783/recent-advances-and-challenges-in-studies-of-control-of-cancer-stem-cells-and-the-gut-microbiome-by-the-trametes-derived-polysaccharopeptide-psp-review
#4
Joseph M Wu, Barbara B Doonan, Tze-Chen Hsieh, Qingyao Yang, Xiao-Tong Yang, Ming-Tat Ling
The medicinal mushroom Trametes versicolor has been well recognized for its activity in maintaining the general health of the population and in managing and treating human diseases in various cultures. Its use has been recently gaining acceptance and popularity in Western countries. The reported health benefits of T. versicolor led to a search for the identity of its bioactive ingredients. These efforts have resulted in the isolation of the polysaccharopeptide PSP from cultured mycelia of strain Cov-1, which expresses large amounts of PSP...
2016: International Journal of Medicinal Mushrooms
https://www.readbyqxmd.com/read/27900661/perceptions-of-study-newsletters-for-older-cancer-patients-in-longitudinal-studies
#5
Mustafa Mohamedali, Joanna Sandoval, Vikarnan Thiruvarooran, Holly Stacey, Meagan O'Neill, Henriette Breunis, Narhari Timilshina, Sara Durbano, Shabbir M H Alibhai
To date, no study has examined the value of providing study newsletters in educating and motivating participants taking part in longitudinal intervention studies and reducing attrition in studies. The study team examined perceptions and satisfaction towards study newsletters, and their potential benefits, in a population of older men with prostate cancer participating in two ongoing longitudinal trials. Two study newsletters issues were mailed out 4 months apart to prostate cancer patients participating in a bone health and/or exercise intervention trial...
November 29, 2016: Journal of Cancer Education: the Official Journal of the American Association for Cancer Education
https://www.readbyqxmd.com/read/27892725/investigational-serine-threonine-kinase-inhibitors-against-prostate-cancer-metastases
#6
Claudio Festuccia
INTRODUCTION: Androgen deprivation therapy (ADT) is used as first therapeutic approach in prostate cancer (PCa) although castration resistant disease (CRPC) develops with high frequency. CRPC is the consequence of lack of apoptotic responses to ADT. Alternative targeting of the androgen axis with abiraterone and enzalutamide, as well as taxane-based chemotherapy were used in CRPC. Serine/threonine protein kinases (STKs) regulate different molecular pathways of normal and neoplastic cells and participate to development of CRPC as well as to the progression towards a bone metastatic disease (mCRPC)...
November 28, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27891225/unraveling-the-role-of-preexisting-immunity-in-prostate-cancer-patients-vaccinated-with-a-her-2-neu-hybrid-peptide
#7
Ioannis F Voutsas, Eleftheria A Anastasopoulou, Panagiotis Tzonis, Michael Papamichail, Sonia A Perez, Constantin N Baxevanis
BACKGROUND: Cancer vaccines aim at eliciting not only an immune response against specific tumor antigens, but also at enhancing a preexisting immunity against the tumor. In this context, we recently reported on the levels of preexisting immunity in prostate cancer patients vaccinated with the HER-2 hybrid peptide (AE37), during a phase I clinical trial. The purpose of the current study was to correlate between preexisting immunity to the native HER-2 peptide, AE36, and expression of HLA-A2 and -A24 molecules with the clinical outcome...
2016: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/27889277/evaluating-the-four-kallikrein-panel-of-the-4kscore-for-prediction-of-high-grade-prostate-cancer-in-men-in-the-canary-prostate-active-surveillance-study
#8
Daniel W Lin, Lisa F Newcomb, Marshall D Brown, Daniel D Sjoberg, Yan Dong, James D Brooks, Peter R Carroll, Matthew Cooperberg, Atreya Dash, William J Ellis, Michael Fabrizio, Martin E Gleave, Todd M Morgan, Peter S Nelson, Ian M Thompson, Andrew A Wagner, Yingye Zheng
BACKGROUND: Diagnosis of Gleason 6 prostate cancer can leave uncertainty about the presence of undetected aggressive disease. OBJECTIVE: To evaluate the utility of a four kallikrein (4K) panel in predicting the presence of high-grade cancer in men on active surveillance. DESIGN, SETTING, AND PARTICIPANTS: Plasma collected before the first and subsequent surveillance biopsies was assessed for 718 men prospectively enrolled in the multi-institutional Canary PASS trial...
November 23, 2016: European Urology
https://www.readbyqxmd.com/read/27879971/tcr-diversity-a-universal-cancer-immunotherapy-biomarker
#9
EDITORIAL
Douglas G McNeel
Sipuleucel-T was approved as a treatment for men with advanced metastatic, castration-resistant prostate cancer on the basis of improved survival in randomized clinical trials. A major challenge for this therapy, as well as other newer cancer immunotherapy agents, has been to identify markers that can identify patients who benefit from these therapies. In a recent manuscript by Sheikh and colleagues, the investigators evaluated changes in T cell clonality in the peripheral blood and tumors of patients treated with sipuleucel-T using next generation sequencing of T cell receptor Vß CDR3 sequences...
2016: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/27876504/disease-and-treatment-characteristics-of-men-diagnosed-with-metastatic-hormone-sensitive-prostate-cancer-in-real-life-analysis-from-a-commercial-claims-database
#10
Thomas W Flaig, Ravi C Potluri, Yvette Ng, Mary B Todd, Maneesha Mehra, Celestia S Higano
BACKGROUND: Our understanding of the clinical characteristics and treatment patterns of men who present with newly diagnosed metastatic (M1) hormone-sensitive prostate cancer is based mainly on clinical trial data. We sought to characterize the M1 population seen in routine clinical practice using a commercial claims database. PATIENTS AND METHODS: A US claims (2000-2013) database was used to identify patients with an index diagnosis of prostate cancer. M1 patients were identified by "International Classification of Diseases, 9th revision, Clinical Modification" diagnosis codes of metastasis to bone, viscera, distant lymph node, and unspecified sites within 90 days of the prostate cancer diagnosis...
October 18, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27875103/diffusion-weighted-imaging-as-a-treatment-response-biomarker-for-evaluating-bone-metastases-in-prostate-cancer-a-pilot-study
#11
Raquel Perez-Lopez, Joaquin Mateo, Helen Mossop, Matthew D Blackledge, David J Collins, Mihaela Rata, Veronica A Morgan, Alison Macdonald, Shahneen Sandhu, David Lorente, Pasquale Rescigno, Zafeiris Zafeiriou, Diletta Bianchini, Nuria Porta, Emma Hall, Martin O Leach, Johann S de Bono, Dow-Mu Koh, Nina Tunariu
Purpose To determine the usefulness of whole-body diffusion-weighted imaging (DWI) to assess the response of bone metastases to treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). Materials and Methods A phase II prospective clinical trial of the poly-(adenosine diphosphate-ribose) polymerase inhibitor olaparib in mCRPC included a prospective magnetic resonance (MR) imaging substudy; the study was approved by the institutional research board, and written informed consent was obtained...
November 22, 2016: Radiology
https://www.readbyqxmd.com/read/27874061/strategies-to-avoid-treatment-induced-lineage-crisis-in-advanced-prostate-cancer
#12
REVIEW
Guilhem Roubaud, Bobby C Liaw, William K Oh, David J Mulholland
The increasing potency of therapies that target the androgen receptor (AR) signalling axis has correlated with a rise in the proportion of patients with prostate cancer harbouring an adaptive phenotype, termed treatment-induced lineage crisis. This phenotype is characterized by features that include soft-tissue metastasis and/or resistance to standard anticancer therapies. Potent anticancer treatments might force cancer cells to evolve and develop alternative cell lineages that are resistant to primary therapies, a mechanism similar to the generation of multidrug- resistant microorganisms after continued antibiotic use...
November 22, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27873555/different-gene-therapy-strategies-a-overview-for-prostate-cancer
#13
Aline Gomes de Souza, Victor Alexandre Felix Bastos, Isaura Beatriz Borges Silva, Karina Marangoni, Vivian Alonso Goulart
Gene therapy emerged as a mighty alternative for conventional treatment of multiple diseases. It has been defined as a product "that mediate their effects by transcription and/or translation of transferred genetic material and/or by integrating into the host genome and that are administered as nucleic acids, viruses, or genetically engineered microorganisms. The products may be used to modify cells in vivo or transferred to cells ex vivo prior to administration to the recipient". The first therapeutic gene therapy human trial was conducted in 1990 by Michael R...
November 15, 2016: Current Gene Therapy
https://www.readbyqxmd.com/read/27871928/the-effect-of-dutasteride-on-mri-defined-prostate-cancer-lesions-mapped-magnetic-resonance-imaging-in-primary-prostate-cancer-after-exposure-to-dutasteride-a-randomized-placebo-controlled-double-blind-clinical-trial
#14
Caroline M Moore, Nicola L Robertson, Fatima Jichi, Adebiyi Damola, Gareth Ambler, Francesco Giganti, Ashley J Ridout, Simon Rj Bott, Mathias Winkler, Hashim U Ahmed, Manit Arya, Anita V Mitra, Neil McCartan, Alex Freeman, Charles Jameson, Ramiro Castro, Giulio Gambarota, Brandon J Whitcher, Clare Allen, Alex Kirkham, Mark Emberton
PURPOSE: Dutasteride is licensed for symptomatic benign prostatic hyperplasia, and has been associated with a lower progression rate in low-risk prostate cancer. We have evaluated the effect of dutasteride on prostate cancer volume as assessed by T2-weighted Magnetic Resonance Imaging (MRI). MATERIALS AND METHODS: In this randomized, double-blind, placebo-controlled trial, men with biopsy-proven low-intermediate risk prostate cancer (up to Gleason 3+4 and PSA up to 15 ng/ml) who had an MR visible lesion of >/= 0...
November 18, 2016: Journal of Urology
https://www.readbyqxmd.com/read/27864015/prediction-of-overall-survival-for-patients-with-metastatic-castration-resistant-prostate-cancer-development-of-a-prognostic-model-through-a-crowdsourced-challenge-with-open-clinical-trial-data
#15
Justin Guinney, Tao Wang, Teemu D Laajala, Kimberly Kanigel Winner, J Christopher Bare, Elias Chaibub Neto, Suleiman A Khan, Gopal Peddinti, Antti Airola, Tapio Pahikkala, Tuomas Mirtti, Thomas Yu, Brian M Bot, Liji Shen, Kald Abdallah, Thea Norman, Stephen Friend, Gustavo Stolovitzky, Howard Soule, Christopher J Sweeney, Charles J Ryan, Howard I Scher, Oliver Sartor, Yang Xie, Tero Aittokallio, Fang Liz Zhou, James C Costello
BACKGROUND: Improvements to prognostic models in metastatic castration-resistant prostate cancer have the potential to augment clinical trial design and guide treatment strategies. In partnership with Project Data Sphere, a not-for-profit initiative allowing data from cancer clinical trials to be shared broadly with researchers, we designed an open-data, crowdsourced, DREAM (Dialogue for Reverse Engineering Assessments and Methods) challenge to not only identify a better prognostic model for prediction of survival in patients with metastatic castration-resistant prostate cancer but also engage a community of international data scientists to study this disease...
November 15, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27862097/phase-ib-trial-of-cabazitaxel-and-tasquinimod-in-men-with-heavily-pretreated-metastatic-castration-resistant-prostate-cancer-mcrpc-the-catch-trial
#16
Andrew J Armstrong, Michael S Humeniuk, Patrick Healy, Russell Szmulewitz, Carolyn Winters, Julie Kephart, Michael R Harrison, Elia Martinez, Kelly Mundy, Susan Halabi, Daniel George
BACKGROUND: Tasquinimod is an immunomodulating and anti-antiangiogenic oral agent with anti-prostate cancer activity in preclinical studies and in clinical trials of men with metastatic castration resistant prostate cancer (mCRPC), including single agent activity and in combination with taxanes. We sought to identify the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of tasquinimod in combination with cabazitaxel and prednisone in men with chemorefractory mCRPC. METHODS: Men with mCRPC who had failed prior docetaxel chemotherapy received cabazitaxel 25 mg/m(2) every 3 weeks with oral tasquinimod at 1 of 3 escalating dose levels (0...
November 16, 2016: Prostate
https://www.readbyqxmd.com/read/27856630/a-prospective-clinical-trial-of-18f-fluciclovine-pet-ct-neoadjuvant-therapy-response-in-invasive-ductal-and-invasive-lobular-breast-cancers
#17
Gary A Ulaner, Debra Goldman, Adriana Corben, Serge Lyashchenko, Mithat Gonen, Jason Lewis, Maura Dickler
: Fluorine-18-labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid ((18)F-Fluciclovine) is a leucine analog radiotracer that depicts amino acid transport into cells. (18)F-Fluciclovine PET/CT visualizes malignancy including prostate cancer, invasive ductal breast cancer (IDC) and invasive lobular breast cancers (ILC). It has not been shown whether changes in (18)F-Fluciclovine avidity reflect changes in tumor burden resulting from treatment. This prospective clinical trial evaluates changes in (18)F-Fluciclovine-avidity compared to breast cancer therapy response, as determined by residual tumor burden on pathology...
November 17, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27847912/testosterone-therapy-in-men-with-testosterone-deficiency-are-we-beyond-the-point-of-no-return
#18
REVIEW
Abdulmaged Traish
Although testosterone therapy in men with testosterone deficiency was introduced in the early 1940s, utilization of this effective treatment approach in hypogonadal men is met with considerable skepticism and resistance. Indeed, for decades, the fear that testosterone may cause prostate cancer has hampered clinical progress in this field. Nevertheless, even after considerable knowledge was acquired that this fear is unsubstantiated, many in the medical community remain hesitant to utilize this therapeutic approach to treat men with hypogonadism...
November 2016: Investigative and Clinical Urology
https://www.readbyqxmd.com/read/27845218/determination-of-the-role-of-negative-magnetic-resonance-imaging-of-the-prostate-in-clinical-practice-is-biopsy-is-still-necessary
#19
Robert S Wang, Eric H Kim, Joel M Vetter, Kathryn J Fowler, Anup S Shetty, Aaron J Mintz, Niraj G Badhiwala, Robert L Grubb, Gerald L Andriole
OBJECTIVES: To assess the negative predictive value (NPV) of multi-parametric MRI (mpMRI) for detection of prostate cancer (PCa) in routine clinical practice, and to identify characteristics of patients for whom mpMRI fails to detect high-grade (Gleason ≥7) disease. METHODS: We reviewed our prospectively maintained database of consecutive men who received prostate mpMRI at our institution, interpreted by a clinical practice of academic radiologists. Between January 2012 and December 2015, 84 men without any MR suspicious regions (MSRs) according to prior institutional classification, or with PI-RADS 1-2 lesions according to the PI-RADS system, underwent standard template transrectal ultrasound-guided (TRUS) prostate biopsy...
November 11, 2016: Urology
https://www.readbyqxmd.com/read/27843209/radioisotopes-in-management-of-metastatic-prostate-cancer
#20
REVIEW
Amar Raval, Tu D Dan, Noelle L Williams, Andrew Pridjian, Robert B Den
INTRODUCTION: Metastatic prostate cancer continues to be a leading cause of morbidity and mortality in men with prostate cancer. Over the last decade, the treatment landscape for patients with castrate-resistant disease has drastically changed, with several novel agents demonstrating an improvement in overall survival in large, multi-institutional randomized trials. Traditional treatment with radioisotopes has largely been in the palliative setting. However, the first in class radiopharmaceutical radium-223 has emerged as the only bone-directed treatment option demonstrating an improvement in overall survival...
October 2016: Indian Journal of Urology: IJU: Journal of the Urological Society of India
keyword
keyword
58398
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"